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Protocol
AbstrACt
Introduction Pain is an expected and appropriate 
experience following traumatic musculoskeletal injury. 
By contrast, chronic pain and disability are unhelpful 
yet common sequelae of trauma-related injuries. 
Presently, the mechanisms that underlie the transition 
from acute to chronic disabling post-traumatic pain are 
not fully understood. Such knowledge would facilitate 
the development and implementation of precision 
rehabilitation approaches that match interventions to 
projected risk of recovery, with the aim of preventing poor 
long-term outcomes. The aim of this study is to identify 
a set of predictive factors to identify patients at risk of 
developing ongoing post-traumatic pain and disability 
following acute musculoskeletal trauma. To achieve this, 
we will use a unique and comprehensive combination 
of patient-reported outcome measures, psychophysical 
testing and biomarkers.
Methods and analysis A prospective observational study 
will recruit two temporally staggered cohorts (n=250 each 
cohort; at least 10 cases per candidate predictor) of 
consecutive patients with acute musculoskeletal trauma 
aged ≥16 years, who are emergency admissions into 
a Major Trauma Centre in the United Kingdom, with an 
episode inception defined as the traumatic event. The 
first cohort will identify candidate predictors to develop 
a screening tool to predict development of chronic and 
disabling pain, and the second will allow evaluation of 
the predictive performance of the tool (validation). The 
outcome being predicted is an individual’s absolute risk 
of poor outcome measured at a 6-month follow-up using 
the Chronic Pain Grade Scale (poor outcome ≥grade 
II). Candidate predictors encompass the four primary 
mechanisms of pain: nociceptive (eg, injury location), 
neuropathic (eg, painDETECT), inflammatory (biomarkers) 
and nociplastic (eg, quantitative sensory testing). 
Concurrently, patient-reported outcome measures will 
assess general health and psychosocial factors (eg, pain 
self-efficacy). Risk of poor outcome will be calculated 
using multiple variable regression analysis.
Ethics and dissemination Approved by the NHS 
Research Ethics Committee (17/WA/0421).
IntroduCtIon 
Pain is an expected and appropriate experi-
ence that usually follows traumatic injury.1 
By contrast, chronic pain and disability are 
unhelpful but common sequelae of trau-
ma-related injuries.2 Gaining an under-
standing of why some people develop 
chronic and disabling post-traumatic pain is 
therefore a priority for individual patients, 
the military and society at large. Notwith-
standing, the mechanisms that underlie the 
transition from acute to chronic disabling 
post-traumatic pain are not fully understood. 
Such knowledge would facilitate the devel-
opment and implementation of a clinical 
strengths and limitations of this study
 ► A comprehensive array of candidate predictive fac-
tors will allow for the prediction of chronic and dis-
abling pain following trauma.
 ► These predictive factors will enable the develop-
ment and validation of a predictive tool to predict 
good and poor outcome at 6 months postinjury.
 ► The prospective design of the study enables control 
of unwarranted influences and enables a stronger 
case for inferring causal relationships.
 ► Identifying predictive factors related to poor out-
come of pain and disability outcome will facilitate 
targeting of effective interventions.
 ► Other candidate predictors may have been useful to 
include (eg, vibration thresholds), but consideration 
of burden to participants of testing and sample size 
considerations necessitated prioritisation of candi-
date predictive factors.
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pathway of care that matches interventions to projected 
risk of poor recovery, with the aim of preventing poor 
long-term outcomes. This project stems from advances in 
knowledge relating to the assessment and management 
of pain3 and the quantification of potential predictive 
factors to inform personalised rehabilitation; identifying 
which patients to target with rehabilitation and when 
and how to target them.
Few studies have specifically explored predictive factors 
for recovery, whether poor or good, following phys-
ical trauma. Of those that have psychosocial variables, 
such as anxiety, depression and post-traumatic stress, 
have so far been identified as the strongest predictors 
of outcome.4–7 However, only a limited number of vari-
ables have hitherto been evaluated as potential predictive 
factors. Indeed, current opinion regarding pain mech-
anisms8 suggests that the development of chronic pain 
and disability cannot be entirely attributable to psycho-
social factors. This is consistent with research in primary 
care that has identified predictive factors for poor 
outcome across a range of musculoskeletal pain condi-
tions,9 which include: widespread pain, high functional 
disability, high pain intensity, long pain duration, high 
depression/anxiety, presence of previous pain episodes, 
movement restriction and poor coping strategies. More-
over, developments in the mechanistic understanding of 
pain10–12 suggest that other measures (eg, indicators of 
central sensitisation and inflammatory activity) may have 
potential predictive utility, especially in an acute trauma 
population.
Aims of study
1. Using a unique combination of (1) general patient 
characteristics including premorbid neuropsycholog-
ical status, (2) quality of life and physical functioning, 
(3) psychosocial features, (4) injury characteristics, 
(5) pain characteristics, (6) quantitative sensory test-
ing and (7) biomarkers, we aim to find a set of predic-
tive factors to identify patients at risk of developing 
ongoing post-traumatic pain and disability following 
acute musculoskeletal trauma. This will subsequently 
inform the feasibility of developing and evaluating a 
new clinical care pathway of precision rehabilitation 
that matches interventions to the predicted risk of 
poor recovery.
objectives
(1) Identify predictive factors for poor outcome (chronic 
pain and disability at 6 months postinjury) following acute 
musculoskeletal trauma. (2) Develop a predictive model 
to inform a screening tool to identify the predicted risk of 
poor recovery (transition from acute post-traumatic pain 
to chronic pain and disability). (3) Estimate the predic-
tive performance of the screening tool through valida-
tion of the model in a separate dataset. (4) Document the 
clinical course of symptoms at 3 and 12 months following 
acute musculoskeletal trauma.
MEthods And AnAlysIs
source of data
The study will be a prospective, observational study of 
two temporally staggered cohorts of patients with trauma, 
who are emergency department admissions into a Major 
Trauma Centre in the United Kingdom, with an episode 
inception defined as the traumatic event (figure 1). The 
first cohort will facilitate development of the prediction 
model to inform the screening tool, and the second will 
enable validation of the prediction model through eval-
uation of the predictive performance of the model and 
tool.13 14 There will be an interval of at least 6 months 
between recruitment into the two respective cohorts. The 
prospective design enables control of unwarranted influ-
ences and enables a stronger case for inferring causal 
relationships. The nature of the study necessitates predic-
tive statistical modelling.15 This protocol is written in line 
with the TRIPOD (transparent reporting of a multivari-
able prediction model for individual prognosis or diag-
nosis) statement,16 in which recommendations are given 
for the reporting of prediction model development and 
validation.
Self-reported and physical assessment predictive data 
will be collected at baseline over a period of up to 14 
days (or duration of inpatient stay if shorter), which 
will commence immediately following recruitment. 
Biomarker data collection will occur throughout the 
same baseline period, but can commence prior to recruit-
ment providing assent is gained from a legal consultee. 
The outcome data will be collected at 6 months postinjury 
(working definition of chronic pain)17, the point of eval-
uation of an individual’s absolute risk of poor outcome 
(objectives 1, 2 and 3). In addition, selected data will be 
measured at 3 and 12 months postinjury to explore the 
clinical course of recovery following injury in the shorter 
and longer terms (objective 4).
Participants
Participants will be recruited from the register of a Major 
Trauma Centre in the United Kingdom for a period 
of up to 24 months (planned start date January 2018). 
All consecutive eligible patients will be approached for 
recruitment until the sample size is achieved.
Eligibility criteria
Inclusion criteria: adult patients aged ≥16 years who are 
admitted to emergency department of the Major Trauma 
Centre, with their main criteria for admission being 
acute musculoskeletal trauma within the preceding 14 
days, and a capacity to use and understand written and 
verbal English language and a mental capacity to provide 
informed consent (eg, no confusion, delirium, severe 
cognitive impairment or severe mental illness, defined 
by a score of ≤6 on the Abbreviated Mental Test).18 The 
primary reason for including patients with trauma occur-
ring up to 14 days, is to be inclusive of patients who are 
critically ill and/or with diminished mental capacity 
initially following their trauma, patients requiring surgery 
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as a result of the trauma and representative of the broad 
trauma population.
Exclusion criteria: exclusions will be made where 
the patient has an acute intracranial lesion (eg, bleed) 
combined with a score of ≤14 on the Glasgow Coma 
Scale19 (a 15-item measure of consciousness impair-
ment with adequate reliability20 that is routinely taken 
in patients with trauma at hospital admission), where 
there is evident brain or central nervous system injury or 
impairment, long-term neurocognitive disorders (such as 
brain tumour, multiple sclerosis, Alzheimer’s and Parkin-
son’s diseases and so on), comorbid cancer, the presence 
of an ongoing rheumatological condition, prolonged 
use of corticosteroids or terminal illness with short life 
expectancy.
Withdrawals: participants will be informed that they 
are free to withdraw from the study at any time, without 
needing to provide reason. In the event of death within 3 
months of being recruited, participants will be automati-
cally withdrawn from the study and the primary predictive 
Figure 1 Study design. CNS, central nervous system. 
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analysis. Baseline data of all withdrawn participants will 
be kept and compared with those of retained participants 
to assess for any differences.
recruitment
Based on feasibility data (site data from the Trauma 
Audit and Research Network), it is estimated that at least 
1000 eligible patients with trauma will be approachable 
for recruitment over a 24-month period, and that 50% 
would be expected to consent to participation. A dedi-
cated team of research nurses will be available to recruit 
patients 7 days per week (from 0700 to 1930).
Because of impairments resulting from their inju-
ries, some otherwise eligible patients will lack the 
mental capacity to provide informed consent when first 
approached to enrol in the study. Recruitment into the 
study will therefore be undertaken under the guidance 
and provision of the (UK) Mental Capacity Act 2005 for 
research in emergency situations. If the patient lacks 
sufficient capacity to consent, written assent for study 
participation will be sought from a legal consultee to 
begin biomarker data collection (blood samples), with 
informed consent for full recruitment (and subsequent 
data collection) being sought from the patient only if, 
and when, they regain sufficient capacity to provide this. 
If the patient does not regain capacity to provide consent 
within 14 days of their trauma, they will not be recruited 
into the study, biomarker data collection will cease and 
any blood samples already collected will be destroyed 
before analysis.
Once informed consent is gained and the participant 
recruited, following a minimum 1 hour lead time after the 
informed consent process (to reduce patient burden), 
members of the research team will visit the patient at 
their bedside to collect baseline self-reported data via 
questionnaires (table 1). On the next available working 
day following completion of the questionnaires (again, to 
reduce patient burden), members of the study team will 
return to the patient to conduct the first physical (quanti-
tative sensory testing) assessment. At each visit, if deemed 
necessary, the capacity of the participant will be checked 
using an Abbreviated Mental Test18 (a score of ≤6 is indic-
ative of reduced capacity), and asked if they are happy to 
proceed with data collection.
outcome
The outcome for the prediction model is an individu-
al’s absolute risk of poor outcome (chronic pain and 
disability) at 6 months postinjury. Outcome will be 
measured using the Chronic Pain Grade Scale (CPGS),21 
which combines pain intensity and pain-related disability 
over the preceding 6 months into a single measure of 
pain severity. The CPGS has previously been used to 
assess the severity of body-wide chronic pain in general 
population,22 primary care23 and post-trauma24 popula-
tions. Each item of the CPGS relates to at least one of 
the three categories of the International Classification of 
Functioning, Disability and Health (ICF)25: impairment, 
activity limitations and restricted participation. Further-
more, all ICF categories are encompassed by the CPGS.26 
The CPGS is a unidimensional scale, with good internal 
consistency across different pain populations; Cronbach’s 
alpha of 0.84 to 0.91 in back pain, 0.79 for headache and 
0.84 for temporomandibular pain.21 27 With regards to 
construct validity, cross-sectional and longitudinal studies 
of general practice patients have shown high scores on the 
CPGS, indicating greater chronic pain, to be associated 
with higher rates of unemployment, greater pain impact 
scale scores, greater use of opioid analgesics and physi-
cian visits, depressed mood and lower self-rated health 
status.21 27 28 For convergent validity, the CPGS has been 
found to have good correlation with equivalent dimen-
sions of the SF-36.27 28 In terms of responsiveness, changes 
in score over time in patients with chronic musculoskel-
etal pain correlated significantly with changes in SF-36 
scores.29 The CPGS has also been shown to have good 
test–retest reliability in primary care patients with back 
pain (weighted kappa 0.81, 95% CI 0.65 to 0.98).27
Although pain persistence is not used in assigning pain 
grade, a measure of pain days in the prior 6 months is 
included in the CPGS.30 The responses on the remaining 
seven items are used for computing scores for the three 
subscales of the CPGS21: characteristic pain intensity, 
disability score and disability points. The characteristic 
pain intensity score (range: 0–100) is obtained by calcu-
lating the mean of three pain intensity measurements: 
‘at the present time’, the ‘worst pain’ in the preceding 
6 months and the ‘average’ pain over the preceding 6 
months. The disability score (range: 0–100) is obtained 
through the mean ratings of how much the pain has 
interfered in performing activities of daily living, recre-
ational, social and family activities, and work (including 
housework) activities in the last 6 months. The disability 
points are scored 0–3 and are derived from a combina-
tion of ranked categories of the number of disability days 
(the number of days that the respondent was away from 
usual activities in the preceding 6 months due to pain) 
and disability score. Based on these scores, the partici-
pant’s chronic pain and disability status can then be clas-
sified into one of the five ordinal categories of chronic 
pain severity21: no pain (Grade 0), low disability and low 
intensity pain (Grade I), low disability and high intensity 
pain (Grade II), high disability and moderately limiting 
intensity pain (Grade III), and high disability and severely 
limiting intensity pain (Grade IV). As in previous studies, 
poor outcome will be defined as grade ≥II.23 31–34
Candidate predictors
Candidate predictors have been selected that are: (1) 
reliable and valid measures of their domain, and (2) 
have a theoretical association with the development of 
chronic pain. Both modifiable and non-modifiable candi-
date predictors are included. Candidate predictors are 
summarised in table 1, with further detail in the online 
supplementary file S1. Table 1 details important data 
that will be measured at 3, 6 and 12 months postinjury to 
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explore the clinical course of recovery following injury in 
the shorter and longer terms. All data collection will be 
standardised through protocols and clinical report forms.
data handling
Blood samples will be collected through the clinical 
and research nurse teams, while the participant is in the 
hospital, and either analysed immediately (C-reactive 
protein) or securely stored for subsequent analysis (cell-
free DNA). Baseline self-reported questionnaires, pain 
and injury drawings, and physical assessments will be 
collected by one of three trained assessors from the study 
team. Inter-rater reliability studies (across two assessors) 
will first be conducted in both healthy and trauma popu-
lations to inform definitive testing protocols. The order 
of physical assessment data collection will be randomly 
assigned (using computerised randomisation software) 
according to the modality of testing and by site, to prevent 
order effects. Follow-up self-reported questionnaires will 
be posted to participants at their home addresses; with up 
to two postal reminders and a telephone call for non-re-
sponse. All questionnaires will be formatted so that data 
can be scanned or entered directly into an electronic 
database. Following data entry, data will be checked by 
a second researcher for completeness and accuracy. In 
addition, regular audits of data collection and storage 
will be performed by an independent study management 
committee. Participant identifiable information will be 
securely stored within the hospital, in line with current 
United Kingdom data protection legislation, and only 
accessible by the site Principal Investigator and Research 
Nurse team who will not be involved in data analysis. All 
outcome measure data will be securely transferred within 
an anonymised database file to physically secure servers 
at the University of Birmingham, and stored for a period 
of 10 years in line with Research Governance procedures. 
Participants will receive usual care and interventions 
received will be recorded for descriptive analysis. Anony-
mised data will be analysed using IBM SPSS Statistics.
sample size
In predictive modelling, a larger sample size enables lower 
bias and variance, and permits the prospective prediction 
of new observations.15 The number of predictors will be 
reduced using exploratory factor analysis. This process will 
ensure that the sample size provides at least 10 cases per 
candidate predictor, to adequately power the final regres-
sion analysis.35 36 Data will be collected for an estimated 
300 participants per cohort (n=600 total) to allow for 
withdrawals (primarily expected deaths within the first 3 
months) and losses to follow-up, so that final data are avail-
able for 250 participants per cohort (n=500 total).
statistical analysis methods and management of missing data
For each cohort, potentially eligible patients, numbers 
examined for eligibility, confirmed eligible, recruited 
into the study, completing follow-up and analysed will be 
reported in a flow diagram. Reasons for non-participation, 
exclusion, drop-outs and withdrawal (eg, death) will be 
reported at each stage. Participant characteristics will be 
descriptively presented. For each variable of interest, the 
number of participants with missing data will be reported.
For the first cohort to develop the predictive model, 
an initial exploratory data analysis stage will summarise 
the data.15 Correlations between candidate predictive 
factors will be calculated at baseline. Outcome (CPGS) 
scores will be dichotomised into good and poor cate-
gories as described previously. Data reduction will 
use exploratory factor analysis to assess factor loading 
of candidate predictors (summary scores) on poor 
outcome at 6 months. This will enable the number of 
candidate predictors entered into the final model to be 
reduced to 25, which can be supported by the cohort 
sample of 250. This process reduces the risk of over-fit-
ting the model and the risk of selecting the wrong vari-
ables due to correlation between predictor variables 
(multicollinearity).37
Statistical modelling for prediction has been planned a 
priori. To explore the influence of each predictive factor on 
poor outcome at 6 months, a logistic multivariable regres-
sion model will be fitted to the dichotomised outcome 
scores to calculate low and high risk of poor outcome. Odds 
ratios for each candidate predictive factor will be reported, 
adjusted for other factors and account for clustering (eg, 
level of injury severity). If necessary, multiple imputation38 
will be used to deal with missing outcome data. The char-
acteristics of those patients with and without 6-month data 
will also be compared, to inform whether patients with no 
6-month data were missing at random. Reduced multivari-
able analyses will be considered if necessary (eg, removing 
one of two candidate predictive factors that are highly 
correlated at baseline), to examine the robustness of the 
conclusions.
risk groups and development of the predictive screening tool
The predictive model will be used to develop a risk strat-
ification tool to inform an individual’s absolute risk of 
poor outcome. The stratification tool will inform clinical 
decision-making for precision rehabilitation. Items will 
be selected for the model if they are statistically signifi-
cantly (P<0.05) associated with poor outcome in the 
logistic regression analysis, and those deemed clinically 
important to retain using expert opinion (regardless of 
statistical significance, study steering group) to improve 
face validity for clinicians and avoid overfitting of the 
model.37 The regression model with included predictive 
factors will be fitted to the data from the first of the two 
cohorts to obtain a final set of parameter estimates (i.e. 
alpha and beta terms), which will be used to form the 
model. An important requirement of the stratification 
tool is that it should be sufficiently brief to facilitate use in 
clinical practice. Thus, we will look to simplify the model 
where possible to facilitate its use, but without important 
reduction in its predictive ability in terms of calibration 
and discrimination. For example, if multi-item ques-
tionnaire scores are included in the model, then we will 
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evaluate whether just one of the questionnaire items is 
sufficient. Ideally, this process will result in a full and 
simplified model.
development versus validation
For validation of the model, data from the second of the 
two cohorts will be compared with that of the first to enable 
analysis of the distribution of important variables, inclusive 
of demographic, predictor and outcome variables. The 
predictive performance of the screening tool (discrimina-
tion, calibration and goodness of fit) will be assessed using 
data from the second cohort. Data in both cohorts will be 
consistent in terms of setting, eligibility criteria, outcome 
and predictors.
dIsCussIon
There is an urgent need for a robust predictive study to 
predict the transition from acute to chronic pain in a muscu-
loskeletal trauma population. Using such a comprehensive 
array of outcome measures will allow the development and 
validation of a predictive tool to predict development of 
chronic and disabling pain, and begin the process of identi-
fying appropriate and precision interventions.
The candidate predictors used in this study have been 
chosen to be as comprehensive as possible, based on 
current knowledge of pain science. Other candidate predic-
tors were considered (eg, microRNA biomarkers), but their 
mechanistic functions and temporal progression are not yet 
sufficiently clear to justify the expense of their inclusion. 
The combination of patient-reported outcome measures, 
psychophysical testing and biomarkers that are included 
are designed to act as surrogates for the four primary mech-
anisms of pain8 39 40: nociceptive (injury location, severity and 
characteristics), neuropathic (painDETECT tool and pain 
extent, inflammatory (biomarkers) and nociplastic (quan-
titative sensory testing, painDETECT and pain location 
and extent). In addition, other patient-reported outcome 
measures (eg, pain intensity, post-traumatic stress, anxiety 
and depression, coping and pain self-efficacy) are included 
as the domains that they measure have been shown to influ-
ence prognosis for long-term outcomes in populations with 
pain in a range of locations.9 23 24
Rehabilitation is widely regarded as an important 
component of post-trauma healthcare41; however, the 
current position of equipoise means that precision reha-
bilitation has not yet been identified. Understanding 
mechanisms that underlie the transition from acute to 
chronic pain is essential to moving beyond this position. 
Identifying predictive factors related to poor outcome 
of pain and disability outcome will facilitate targeting of 
effective interventions. This will inform rehabilitation 
decision-making and facilitate improvements in clinical 
and cost-effectiveness of rehabilitation interventions.
Limited research has identified criteria for quality in a 
predictive model, but authors have identified potential 
quality issues to ensure methodological rigour.42 These 
issues are summarised in table 2 and incorporated into the 
study design to ensure low risk of bias in development and 
validation of the predictive model.
Patient burden and potential distress
The primary ethical concern is to limit distress on partic-
ipants. As such, to reduce the patient burden when 
collecting baseline data, the self-reported questionnaires 
will be administered by members of the study team 
shortly following obtaining fully informed consent, and 
physical assessment outcomes will be measured at least 
24 hours later. Patients will be asked for consent to not 
only provide new data for the study, but also for the study 
team to access information that will have been routinely 
collected by the hospital staff since the time of admission 
(eg, nature and circumstances of injury, medical history, 
medication details and blood test results). This will be 
fully explained to patients and explicitly detailed in the 
participant information sheet.
Mental capacity
Because of the nature of their injuries, the patient’s mental 
capacity will be assessed on admission into hospital and 
thereafter by clinical staff and/or research nurses. The 
mental capacity of eligible patients at the time of being 
approached for recruitment will therefore fall into one 
of two groups: either they possess or are lacking mental 
capacity (in accordance with the Mental Capacity Act 
2005) to provide informed consent to voluntarily partici-
pate in the study.
For patients possessing mental capacity to provide 
consent, a research nurse or member of the research 
team will ask if they are interested in participating in 
the study. If they are interested, a copy of the participant 
information sheet will be provided (and if necessary read 
to them) to give them an outline of the study. Following 
an opportunity to seek additional information and ask 
questions, the patient will be asked if they wish to provide 
their written informed consent to participate in the study, 
at which point a consent form will need to be signed.
On admission to the hospital, an otherwise eligible 
patient may lack the mental capacity to decide whether 
to provide consent to participate in a research study 
(eg, due to the severity of their injuries, because they 
are arriving intubated and ventilated, or as a side-effect 
of medication for their injuries). They may or may not 
regain this capacity during their stay in the hospital. Due 
to our wish to begin measuring biomarkers as early as 
possible following the onset of trauma, for some other-
wise eligible patients it would be necessary to take blood 
samples before the patient has regained the capacity 
to provide informed consent. Using the convention of 
previous studies in trauma populations,43 recruitment 
into the study will be undertaken under the provision and 
guidance of the Mental Capacity Act 2005 for research 
in emergency situations, and in accordance with the 
Declaration of Helsinki. As such, if a patient does not 
possess this capacity when first approached for recruit-
ment, the research team will request a mandate to collect 
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blood samples from a legal consultee. This mandate can 
continue until the patient gains sufficient capacity to 
make an informed decision as to whether they wish to 
provide consent or not. We will use this mandate up to 
14 days from the date of the trauma. If the patient does 
not regain capacity within 14 days following the trauma, 
or if informed consent is not provided by the patient 
once capacity to do so is regained, any samples collected 
will be destroyed before any non-clinical biomarker 
analysis (i.e. cell-free DNA) is performed. Furthermore, 
only once informed consent has been gained from the 
patient would the research team proceed to collect any 
Table 2 Methodological decisions to improve study quality
Criteria42 Methodological decisions to improve quality
Study design
  Inception cohort  ► Clear description of population
 ► Clear description of the participants at baseline
  Source population  ► Clear description of population
 ► Clear description of sampling frame and recruitment (method and 
timing)
  Inclusion and exclusion criteria  ► Clarity of eligibility criteria
  Prospective design  ► Clarity of study design
Study attrition
  Number of drop-outs  ► Adequate participation rate
 ► Clear description of attempts to collect information on participants who 
dropped out
 ► Reporting numbers and reasons for loss to follow-up
  Information provided on method of management 
of missing data
 ► Appropriate methods of imputation of missing data
Predictive factors
  All predictive factors described used to develop 
the model
 ► Clear definition of predictive factors
 ► An adequate proportion of participants has complete data for the 
predictive factor
  Standardised or valid measurements  ► The measurement of the predictive factor is reliable and valid
 ► The measurement of the predictive factor is the same for all participants
  Linearity assumption studied  ► Linearity of data will be reported
  No dichotomisation of predictive variables  ► Continuous variables will be reported where possible
  Data presentation all predictive factors  ► Complete data will be presented
Outcome measures
  Description of outcome measures  ► The outcome is clearly defined
  Standardised or valid measurements  ► The measurement of the outcome is reliable and valid
 ► The measurement of the outcome is the same for all participants
  Data presentation of most important outcome 
measures
 ► Complete data will be presented
Analysis
  Presentation of univariate crude estimates  ► An appropriate strategy for model building is described
 ► An adequate statistical model described
  Sufficient numbers of subjects per variable  ► Adequate data will be presented
  Selection method of variables explained  ► Sufficient data will be presented to enable assessment of the adequacy 
of the analytic strategy
 ► All results will be reported
  Presentation of multivariate estimates  ► An appropriate strategy for model building is described
 ► An adequate statistical model described
Clinical performance/validity
  Clinical performance  ► Clinical performance of the model will be reported
  Internal validation  ► Internal validation will be reported
  External validation Not a focus of this study
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self-reported questionnaire or physical assessment data. 
The legal consultee can either be a ‘personal consultee’, 
for example, family member, or a ‘nominated consultee’, 
for example, intensive care consultant. Once a consultee 
(personal or nominated) has been identified, they will 
be provided with the participant information sheet, to 
inform them about the study. The consultee will be asked 
if they feel participating in the study would be something 
to which the patient would agree or object to. If, in their 
opinion, the patient would agree to participating in the 
study, the consultee will be asked to sign a declaration 
form, and the research team can begin the schedule 
of blood sample collections. If, at any time prior to the 
patient regaining capacity, the consultee decides to with-
draw assent, then no further samples will be collected 
until the patient can be approached for formal recruit-
ment (if appropriate).
other ethical issues
Participants will be informed that they are free to with-
draw from the study at any time, without needing to 
provide reason. At each data collection visit, the capacity 
of the participant will be checked (using an Abbreviated 
Mental Test) and asked if they are happy to proceed with 
data collection. Any concerns for a participant by the study 
team will be fed back to clinical staff. All blood samples will 
be collected by hospital staff and the research nurse team 
and will be stored, tested and disposed of in accordance 
with current United Kingdom guidelines and regulations. 
In the event of death within 3 months of being recruited, 
participants will be automatically withdrawn from the study 
and the primary predictive analysis. Baseline characteristics 
of withdrawn participants will be compared with those of 
retained participants to assess for any differences.
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